RxDoctor Payments Data

Daniel Bonnette

Ophthalmology · West Monroe, LANPI 1093235491

Payments from drug & device makers

$3,175in general payments, 2019–2025

Across 61 payments — averaging $52.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • NEW World Medical,inc.$793
  • Glaukos Corporation$299
  • AbbVie$279
  • Regeneron Healthcare Solutions, Inc.$124
  • Sight Sciences, Inc.$97
  • plus $333 from 9 others

What the payments were for

  • Food & beverage$3,159100%
  • Entertainment$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,175 in reported general payments places this provider in the 60th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$333,996
Medicare patients
1,107
Services billed
4,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine34$35,264
Prednisolone Acetate397$21,776
MieboPerfluorohexyloctane/Pf17$12,275
CombiganBrimonidine Tartrate/Timolol26$11,506
RocklatanNetarsudil Mesylat/Latanoprost23$10,880
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol47$10,673
Latanoprost778$10,628
Cyclosporine16$9,353
MoxifloxacinMoxifloxacin Hcl406$8,325
TyrvayaVarenicline Tartrate11$6,787
LumiganBimatoprost13$6,155
Ketorolac Tromethamine355$5,952
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat242$4,922
VyzultaLatanoprostene Bunod13$3,883
Travoprost16$3,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$279$52,92673 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$43$16,15830 claims
Oyster Point Pharma, Inc.Tyrvaya$54$6,78711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in West Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →